



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: A61K 31/4745, A61P 25/28	A1	(11) International Publication Number: WO 00/40244 (43) International Publication Date: 13 July 2000 (13.07.2000)
(21) International Application Number: PCT/IB00/00011 (22) International Filing Date: 06 January 2000 (06.01.2000) (30) Priority Data: 990100005 07 January 1999 (07.01.1999) GR (60) Parent Application or Grant P.N. GEROLYMATOS S.A. [/]; (). XILINAS, Michel [/]; (). GEROLYMATOS, Panayotis, Nikolas [/]; (). XILINAS, Michel [/]; (). GEROLYMATOS, Panayotis, Nikolas [/]; (). RASMUSSEN, Torben, Ravn ; ().	Published	
(54) Title: USE OF PHANQUINONE FOR THE TREATMENT OR PREVENTION OF MEMORY IMPAIRMENT (54) Titre: UTILISATION DE PHANQUINONE POUR LE TRAITEMENT OU LA PREVENTION DES TROUBLES MNESIQUES		
(57) Abstract <p>The use of phanquinone (4,7-phenanthroline-5,6-dione) for the treatment or prevention of memory impairment is suggested. Also a method for improving the learning or memory of a normal subject is suggested, said method comprising the administering of phanquinone, optionally together with one or more pharmaceutically acceptable carrier(s).</p> (57) Abrégé <p>L'invention concerne l'utilisation de phanquinone (4,7-phénanthroline-5,6-dione) pour le traitement ou la prévention des troubles mnésiques. Elle concerne également une méthode permettant d'améliorer l'apprentissage ou la mémoire chez un sujet normal, qui consiste à administrer à ce dernier de la phanquinone, éventuellement associée à un ou plusieurs excipients pharmaceutiquement acceptables.</p>		

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 31/4745, A61P 25/28	A1	(11) International Publication Number: WO 00/40244 (43) International Publication Date: 13 July 2000 (13.07.00)
(21) International Application Number: PCT/IB00/00011 (22) International Filing Date: 6 January 2000 (06.01.00) (30) Priority Data: 990100005 7 January 1999 (07.01.99) GR (71) Applicant (for all designated States except US): P.N. GEROLYMATOS S.A. [GR/GR]; 13 Asklipiou Street, GR-145 65 Kryoneri Attika (GR). (72) Inventors; and (75) Inventors/Applicants (for US only): XILINAS, Michel [FR/CY]; Yalos Village G 105, 7000 Meneou, Chypre (CY). GEROLYMATOS, Panayotis, Nikolas [GR/GR]; 13 Asklipiou Street, GR-145 65 Kryoneri Attika (GR). (74) Agents: RASMUSSEN, Torben, Ravn et al.; International Patent-Bureau, 23 Høje Taastrup Boulevard, DK-2630 Taastrup (DK).		(81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), DM, EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: USE OF PHANQUINONE FOR THE TREATMENT OR PREVENTION OF MEMORY IMPAIRMENT (57) Abstract The use of phanquinone (4,7-phenanthroline-5,6-dione) for the treatment or prevention of memory impairment is suggested. Also a method for improving the learning or memory of a normal subject is suggested, said method comprising the administering of phanquinone, optionally together with one or more pharmaceutically acceptable carrier(s).		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Description

5

10

15

20

25

30

35

40

45

50

55

5

1

10

USE OF PHANQUINONE FOR THE TREATMENT OR PREVENTION OF -
MEMORY IMPAIRMENT.

5 FIELD OF THE INVENTION

15

20

The present invention relates to the treatment or prevention of memory impairment and to a method of improving the learning and memory capabilities of normal subjects. Notably, the invention relates to the use of phanquinone for the prevention or treatment of memory impairment and to a method comprising the administering of phanquinone for improving the learning and the memory capabilities of a normal subject.

25

15 DESCRIPTION OF THE BACKGROUND ART

30

35

Memory is a complex mental function which includes the ability to learn, retain, and recall information. Memory impairment is often a symptom of dementia, amnesia, aphasia, senility, or age-associated cognitive deterioration. Dementia may be caused by i.a. Alzheimer's disease, Parkinson's disease, progressive supranuclear palsy, and amyotrophic lateral sclerosis.

40

45

Two types of memory are generally recognized, viz. short-term and long-term memory. The short-term memory is the ability to learn and briefly retain small amounts of information for a few seconds or minutes and to recall the information again. The long-term memory is the ability to learn and retain large amounts of information and recall those after long delays. Impairment of both types of memory may be symptoms of dementia.

50

The short-term memory is impaired for persons suffering from dementia in the early stages. Such persons have difficulty in learning new information and to retain it more than momentarily. As the disease

55

CONFIRMATION COPY

5

2

10

progresses, new learning is severely curtailed and, gradually, the long-term memory is also lost.

Several compounds or mixtures of compounds have been suggested in the prior art for the treatment of mental decline.

15

20

25

30

35

Pyrrolidone or pyrrolidine derivatives for improving memory have been suggested in EP 239500, EP 165919, BE 892942, US 5102882, EP 296978, EP 296979. Pyridine derivatives for the treatment of impairment of short-term memory are disclosed in US 4448779. Choline derivatives for treating mental decline in the elderly is suggested in EP 201623. Indole or indolin derivatives for the improvement of processes involved in learning are disclosed in EP 241006, JP 6107544, US 5494928, WO 97/47598, and US 4778812. Pilocardin derivatives for improving memory functions are disclosed in US 4977176. Glycine-containing compositions for enhancing cognitive functions are disclosed in US 5731349. Peptide derivatives for treating mental decline and improving mental capacity are disclosed in US 5439930, RU 2099078, and WO 95/15310. Xanthine derivatives for the treatment of age-related memory impairment are disclosed in WO 94/19349.

40

45

50

Compounds enhancing the stimulus-induced release of neurotransmitters, especially acetylcholine, may also be used to treat memory impairment. Examples are 2-benzyl-2-propyl 2-amino-2-R-acetate derivatives disclosed in EP 293351, 1-(4-chlorophenyl)-2-methyl-2-propyl 2-amino-3-methyl-butanoate disclosed in GB 2205097, polycyclic hetero-aromatic derivatives disclosed in US 5300642, 5-phenyl-4,4-dimethyl-3-oxo or hydroxy-pentylamine derivatives disclosed in EP 322391, 1-oxa-8-azaspiro(4.5)decane derivatives disclosed in EP 491562, derivatives of azacyclic and azabicyclic hydroxylamine disclosed in WO 94/00448, halogenated

55

5

3

10

aromatic derivatives disclosed in EP 627400, derivatives of acyclic and cyclic amides disclosed in WO 95/29909, carbamoyloxypropylamine or carbamoyloxyethylamine derivatives disclosed in WO 96/08468.

15

5 Compounds that modulate the function of the kainate receptor may be used for improving memory. An example is alkyl carboxy amino acids, such as (2S,4R)-4-methyl glutamic acid, disclosed in WO 96/25387.

20

10 In EP 326381 it is suggested to use hypothalamic hypophysiotropic hormones, such as somatostatin and growth-hormone releasing factor, to improve the learning abilities.

25

DE 2555010 discloses the use of uronic acids for improving the cerebral efficiency in general, such as 15 improvement of memory.

30

US 4481206 discloses the improvement of memory when administering spiro(N'-methyl-4'-piperidyl)-N-ethyl-succinimide. This compound is a parasympathicomimetic substance also having cholinomimetic, analgetic 20 and sedative activity.

35

WO 98/33498 discloses the use of breflate or analogous compounds thereof for the treatment of a mammal suffering from a cognitive dysfunction. Breflate or analogous compounds thereof enhance the long-term 25 potential of nerve cells.

40

Phanquinone (4,7-phenanthroline-5,6-dione) has hitherto been used for the treatment of various disorders, such as amoebiasis. However, the treatment or prevention of memory impairment has not been suggested 30 previously. Phanquinone has been marketed by CIBA-GEIGY as ENTOBEX®.

45

50

It is the object of the invention to provide a new use of a known pharmaceutical compound for the treatment or prevention of memory impairment. Another object 35 of the invention is to provide a method of treating a

55

5

4

10

subject suffering from or suspected of suffering from memory impairment. A further object of the invention is to provide a method for improving the learning and memory ability of a normal subject.

5

15

DISCLOSURE OF THE INVENTION

20

According to the present invention the use of phanquinone for the manufacture of a pharmaceutical composition for the treatment or prevention of memory impairment is provided.

25

Phanquinone may be administered in any amount efficient for the treatment or prevention of memory impairment. Preferably, phanquinone is administered in an amount of 5 mg to 250 mg, and most preferred 10 mg to 50 mg, one to three times daily. The pharmaceutical composition may be formulated for oral, parenteral or intradermal administration.

30

According to the present invention also a method for improving the learning or memory of a normal subject is provided, said method comprising the administering of phanquinone, optionally together with one or more pharmaceutically acceptable carrier(s). Phanquinone may be administered in any amount effective to improve the learning or the memory.

35

The invention also relates to a method of treating a subject suffering from or suspected of suffering from memory impairment, said method comprising administering to the subject an amount of phanquinone effective to treat or prevent the memory impairment.

40

According to the present invention also a method of treating a subject suffering from or suspected of suffering from memory impairment is provided, said method comprising administering to the subject an amount of phanquinone effective to improve learning or memory.

45

50

35 memory.

55

5

5

Phanquinone possesses a long-term as well as a short-term effect on the memory.

The short-term effect implies that the ability to retain and recall information from the memory is improved compared to the normal state, when phanquinone is administered immediately prior to a trial.

The long-term effect implies that the memory improving effect of phanquinone still is obtained several days after the administration has ceased.

The exact function of phanquinone in the body is not known yet. However, as the effect of phanquinone is pronounced in all parts of memory formation, including learning, retaining and recalling information, the effect of phanquinone is considered to be unspecific. Most likely, the effect of phanquinone is referred to enhanced arousal. This hypothesis is supported by the fact, that a general enhancement of activity is observed.

The above attempt to explain the observed effects of phanquinone is without prejudice to the scope of protection sought and must not be construed as limiting the invention to a specific mode of action.

DETAILED DESCRIPTION OF THE INVENTION.

Phanquinone is preferably administered together with one or more pharmaceutical acceptable carrier(s). The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipients thereof. In a preferred embodiment, the phanquinone and optional further active constituents in a pharmaceutical composition are purified.

It will be appreciated that the amount of phanquinone and optional further active constituents required for said treatment, improvement or prevention

55

5

6

10

will vary according to the route of administration, the disorder to be treated, the condition, age, the case history of the subject, the galenic formulation of the pharmaceutical composition, etc.

15

5 In general, a suitable therapeutically effective amount of phanquinone in the pharmaceutical composition would be e.g. 5 to 250 mg, preferably 10 to 50 mg.

20

The actually administered amounts of phanquinone and optional further active constituents may be decided 10 by a supervising physician. If the pharmaceutical composition in addition to phanquinone comprises further active constituents those may be included therein for administering in combination concurrently, 25 or in different compositions for administering substantially simultaneously but separately, or sequentially.

25

30

Therapeutic formulations include formulations suitable for parenteral (including intramuscular and intravenous), oral, rectal or intradermal administration, although oral administration is the preferred 20 route. Thus, the pharmaceutical composition may be formulated as tablets, pills, syrups, capsules, suppositories, formulations for transdermal application, 35 powders, especially lyophilized powders for reconstitution with a carrier for intravenous administration, etc. 25

35

40

The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which phanquinone is administered. The carriers in the pharmaceutical composition may comprise a binder, such as microcrystalline cellulose, polyvinylpyrrolidone (polyvidone or povidone), 45 gum tragacanth, gelatine, starch, lactose or lactose monohydrate; a disintegrating agent, such as alginic acid, maize starch and the like; a lubricant or surfactant, such as magnesium stearate, or sodium 50 lauryl sulphate; a glidant, such as colloidal silicon

50

55

5

7

10

dioxide; a sweetening agent, such as sucrose or saccharin; and/or a flavouring agent, such as peppermint, methyl salicylate, or orange flavouring.

15

Therapeutic formulations suitable for oral administration, e.g. tablets and pills, may be obtained by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by mixing the constituent(s), and compressing this mixture in a suitable apparatus into tablets having a suitable size. Prior to the mixing, the phanquinone may be mixed with a binder, a lubricant, an inert diluent and/or a disintegrating agent and further optionally present constituents may be mixed with a diluent, a lubricant and/or a surfactant.

25

30

In a preferred embodiment, free-flowing phanquinone powder is mixed with a binder, such as microcrystalline cellulose, and a surfactant, such as sodium lauryl sulphate, until a homogeneous mixture is obtained. Subsequently, another binder, such as polyvidone, is transferred to the mixture under stirring. Said mixture is passed through granulating sieves and dried by desiccation before compression into tablets in a standard compressing apparatus.

35

40

In a second preferred embodiment, free-flowing phanquinone powder is mixed with surfactants and/or emulsifying agents, such as Sapamine® (N-(4'-stearoyl amino phenyl)-trimethylammonium methyl sulphuric acid) and lactose monohydrate until a uniform distribution of the constituents is obtained. A second preparation containing a disintegrating agent, such as maize starch, is added to the phanquinone mixture under continuous stirring. Such a second preparation may be obtained by adding excess boiling water to maize starch suspended in cold water. The final mixture is granulated and dried as above and mixed with maize starch

45

50

55

5

8

10

and magnesium stearate and finally compressed into tablets in a standard apparatus.

15

A tablet may be coated or uncoated. An uncoated tablet may be scored. A coated tablet may be coated with sugar, shellac, film or other enteric coating agents.

20

Therapeutical formulations suitable for parenteral administration include sterile solutions or suspensions of the active constituents. An aqueous or oily carrier may be used. Such pharmaceutical carriers may be sterile liquids, such as water and oils, including petroleum, animal, vegetable or synthetic origin, such as peanut oil, soy bean oil, mineral oil, sesame oil and the like. Formulations for parenteral administration also include a lyophilized powder comprising phanquinone and optionally further active constituents that is to be reconstituted by dissolving in a pharmaceutically acceptable carrier dissolving the active constituents, e.g. an aqueous solution of carboxymethylcellulose and lauryl sulphate.

25

30

35

When the pharmaceutical composition is a capsule, it may contain a liquid carrier, such as a fatty oil, e.g. cacao butter.

40

45

Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatine, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim-milk, glycerol, propylene, glycol, water, ethanol and the like. Said compositions may form solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides.

50

In one embodiment of the pharmaceutical composition according to the invention, phanquinone and the

55

5

9

10

possible further active constituents, are comprised as separate pharmaceutical entities. The two entities may be administered simultaneously or sequentially.

Other features and advantages of the invention will be apparent for the skilled person.

15

EXAMPLE 1

Preparation of a pharmaceutical composition comprising phanquinone

20

10 250 g of phanquinone was mixed with 200 g sapa-
mine® (N-(4'-stearoyl amino-phenyl)-trimethylammonium
methyl sulphuric acid) and 1025 g lactose mono-hydrate
for a period of 5 minutes. 300 g of boiling water was
25 added at a time to a mixture of 100 g maize starch in
15 100 g cold water. The maize suspension, cooled to 40°C,
was added to the phaniquinone-containing powder mixture
under continuous stirring. The mixture was granulated
30 using a 2.5 mm sieve and desiccated for 18 hours at
40°C. The dry granules were mixed with 400 g maize
20 starch and 20 g magnesium stearate. The final mixture
was formulated into tablets having a diameter of 8.0 mm
and a weight of 200 mg.

35

40

45

50

55

Claims

5

10

15

20

25

30

35

40

45

50

55

5

10

P A T E N T C L A I M S

10

1. A use of phanquinone for the manufacture of a pharmaceutical composition for the treatment or prevention of memory impairment.

15

2. A use according to claim 1, wherein planquinone is administered in an amount of 5 mg to 250 mg one to three times daily.

20

3. A use according to any of the claims 1 or 2, wherein phanquinone is administered in an amount of 10 mg to 50 mg one to three times daily.

25

4. A use according to any of the claims 1 to 3, wherein the pharmaceutical composition is formulated for oral, parenteral or intradermal administration.

5. A method for improving the learning or memory of a normal subject, comprising the administering of phanquinone, optionally together with one or more pharmaceutically acceptable carrier(s).

30

6. A method of treating a subject suffering from or suspected of suffering from memory impairment comprising administering to the subject an amount of phanquinone effective to treat or prevent the memory impairment.

35

7. A method of treating a subject suffering from or suspected of suffering from memory impairment comprising administering to the subject an amount of phanquinone effective to improve learning or memory.

40

8. A method according to any of the claims 5 to 7, wherein the amount of phanquinone is 5 mg to 250 mg.

9. A method according to claim 5 to 7, wherein the amount of phanquinone is 10 mg to 50 mg.

45

10. A method according to any of the claims 5 to 7, wherein the subject is human.

11. A method according to any of the claims 5 to 7, wherein phanquinone is administered for up to ten years.

50

55

5

11

10

12. A method according to any of the claims 5 to 7, wherein phanquinone is formulated for oral administration.

15

13. A method according to any of the claims 5 to 7, wherein phanquinone is formulated for parenteral administration.

20

14. A method according to any of the claims 5 to 7, wherein phanquinone is formulated for intradermal administration.

10

25

30

35

40

45

50

55

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IB 00/00011

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/4745 A61P25/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 99 09981 A (XILINAS MICHEL ;GEROLYMATOS PANAYOTIS NIKOLAS (GR); GEROLYMATOS P) 4 March 1999 (1999-03-04) * p.1, 1.13-16; claims 1-3, 59-60 *	1-14

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

22 February 2000

Date of mailing of the international search report

29/02/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Uiber, P

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/IB 00/00011

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9909981 A	04-03-1999	AU 8124198 A	16-03-1999
		AU 1502799 A	26-07-1999
		WO 9934807 A	15-07-1999
		US 5994323 A	30-11-1999
<hr/>			